| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis M Pàez-Ribes, E Allen, J Hudock, T Takeda, H Okuyama, F Viñals, ... Cancer cell 15 (3), 220-231, 2009 | 2844 | 2009 |
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors O Casanovas, DJ Hicklin, G Bergers, D Hanahan Cancer cell 8 (4), 299-309, 2005 | 1899 | 2005 |
| Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling R Benedito, SF Rocha, M Woeste, M Zamykal, F Radtke, O Casanovas, ... Nature 484 (7392), 110-114, 2012 | 439 | 2012 |
| Unraveling the role of angiogenesis in cancer ecosystems I Zuazo-Gaztelu, O Casanovas Frontiers in Oncology 8, 248, 2018 | 318 | 2018 |
| Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing S Melo, A Villanueva, C Moutinho, V Davalos, R Spizzo, C Ivan, S Rossi, ... Proceedings of the National Academy of Sciences 108 (11), 4394-4399, 2011 | 288 | 2011 |
| The p21Cip1 protein, a cyclin inhibitor, regulates the levels and the intracellular localization of CDC25A in mice regenerating livers M Jaime, MJ Pujol, J Serratosa, C Pantoja, N Canela, O Casanovas, ... Hepatology 35 (5), 1063-1071, 2002 | 275 | 2002 |
| Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice F Maione, S Capano, D Regano, L Zentilin, M Giacca, O Casanovas, ... The Journal of clinical investigation 122 (5), 1832-1848, 2012 | 209 | 2012 |
| Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner O Casanovas, F Miró, JM Estanyol, E Itarte, N Agell, O Bachs Journal of Biological Chemistry 275 (45), 35091-35097, 2000 | 191 | 2000 |
| Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination C Anderberg, SI Cunha, Z Zhai, E Cortez, E Pardali, JR Johnson, ... Journal of Experimental Medicine 210 (3), 563-579, 2013 | 150 | 2013 |
| Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) E Grande, J Capdevila, D Castellano, A Teulé, I Durán, J Fuster, I Sevilla, ... Annals of oncology 26 (9), 1987-1993, 2015 | 147 | 2015 |
| Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients G Jiménez-Valerio, M Martínez-Lozano, N Bassani, A Vidal, ... Cell reports 15 (6), 1134-1143, 2016 | 121 | 2016 |
| Antiangiogenic therapies: going beyond their limits L Moserle, G Jiménez-Valerio, O Casanovas Cancer discovery 4 (1), 31-41, 2014 | 119 | 2014 |
| PTEN mediates Notch-dependent stalk cell arrest in angiogenesis H Serra, I Chivite, A Angulo-Urarte, A Soler, JD Sutherland, ... Nature communications 6 (1), 7935, 2015 | 118 | 2015 |
| The protein SET regulates the inhibitory effect of p21Cip1 on cyclin E-cyclin-dependent kinase 2 activity JM Estanyol, M Jaumot, O Casanovas, A Rodriguez-Vilarrupla, N Agell, ... Journal of Biological Chemistry 274 (46), 33161-33165, 1999 | 117 | 1999 |
| Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches K Oberg, O Casanovas, JP Castaño, D Chung, G Delle Fave, P Denèfle, ... Clinical Cancer Research 19 (11), 2842-2849, 2013 | 115 | 2013 |
| TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence I Puig, SP Tenbaum, I Chicote, O Arques, J Martinez-Quintanilla, ... The Journal of clinical investigation 128 (9), 3887-3905, 2018 | 108 | 2018 |
| Metronomic chemotherapy following the maximum tolerated dose is an effective anti‐tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells M Vives, MM Ginestà, K Gracova, M Graupera, O Casanovas, G Capellà, ... International journal of cancer 133 (10), 2464-2472, 2013 | 104 | 2013 |
| Anti‐angiogenesis and metastasis: a tumour and stromal cell alliance L Moserle, O Casanovas Journal of internal medicine 273 (2), 128-137, 2013 | 103 | 2013 |
| ALK1 loss results in vascular hyperplasia in mice and humans through PI3K activation E Alsina-Sanchís, Y García-Ibáñez, AM Figueiredo, C Riera-Domingo, ... Arteriosclerosis, Thrombosis, and Vascular Biology 38 (5), 1216-1229, 2018 | 102 | 2018 |
| Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action I Duran, J Lambea, P Maroto, JL González-Larriba, L Flores, ... Targeted oncology 12, 19-35, 2017 | 99 | 2017 |
August Vidal i BelHospital Universitari de Bellvitge-IDIBELL確認したメール アドレス: bellvitgehospital.cat